PropertyValue
?:abstract
  • Severe SARS-CoV-2 infection is linked to the presence of autoantibodies against multiple targets, including phospholipids and type-I interferons. We recently identified activation of an autoimmune-prone B cell response pathway as correlate of severe COVID-19, raising the possibility of de novo autoreactive antibody production during the antiviral response. Here, we identify autoreactive antibodies as a common feature of severe COVID-19, identifying biomarkers of tolerance breaks that may indicate aggressive immunomodulation.
is ?:annotates of
?:creator
?:doi
  • 10.1101/2020.10.21.20216192
?:doi
?:journal
  • medRxiv_:_the_preprint_server_for_health_sciences
?:license
  • medrxiv
?:pdf_json_files
  • document_parses/pdf_json/d2dee8b8b68a5dc9736433ba0fd02448722923a6.json
?:pmid
?:pmid
  • 33106819.0
?:publication_isRelatedTo_Disease
is ?:relation_isRelatedTo_publication of
?:sha_id
?:source
  • MedRxiv; Medline; WHO
?:title
  • Broadly-targeted autoreactivity is common in severe SARS-CoV-2 Infection
?:type
?:year
  • 2020-10-23

Metadata

Anon_0  
expand all